A Common Masquerade in AMD

The challenge of managing non-vascularized retinal pigment epithelial detachments.

Abed Namavari, MD,  and Philip J. Rosenfeld, MD, PhD
By
The irreversible loss of vision in late stage age-related macular degeneration is associated with fovea-involving geographic atrophy and macular neovascularization.1 No treatment currently exists to slow the progression of geographic atrophy, but anti-VEGF agents can effectively treat neovascular AMD.2

 
These patients may need injections as frequently as every month to eliminate the macular fluid and avoid the consequences of inadequately treating macular neovascularization (MNV), which include irreversible vision loss from macular hemorrhages and scar formation. While this fluid can reside within the retina, under the retina and under the retinal pigment epithelium, the most challenging fluid to treat is that below the RPE that presents as a retinal pigment epithelial detachment (PED).3

Where ICGA is Helpful
In the past, we depended on fluorescein and indocyanine green angiography to identify and characterize these neovascular lesions, but over the past decade, optical coherence tomography has emerged as the principal imaging technique for patients with neovascular AMD.4

While OCT imaging can identify macular fluid in the different anatomic compartments of the macula and monitor fluid response to anti-VEGF therapy, at times it can be difficult to distinguish between macular fluid arising from neovascularization and that arising as a manifestation of non-vascularized AMD, such as subretinal fluid within the valley between drusen5 and the sub-RPE fluid that forms serous non-vascularized PEDs, which can also include pockets of subretinal fluid at the apex of the PED.6

ICGA can be helpful in identifying the neovascularization in PED if it exists.1 Often, type 1 neovascularization can be identified at the edge of the PED, or within a notch at the edge of the PED, and type 3 neovascularization can appear as a hot-spot within the retina on top of the PED. These type 3 lesions are usually also associated with intra-retinal fluid overlying the PED as well. But, what about those serous PEDs in which no neovascular lesion is obvious on angiography?

 
If the neovascular lesion is present but not detected using dye-based or OCT angiography, then the consequences of not treating could be catastrophic. Enlarging PEDs can contribute to RPE tears resulting in significant vision loss from submacular hemorrhage. Clinicians often err on the side of caution and treat these lesions because they could be vision-threatening, only to find out later that the PED and associated subretinal fluid are refractory to therapy.  

Characteristics Of Non-vascularization
Over the years, we have identified some characteristic features on OCT that suggest when drusenoid or serous PEDs are not vascularized. If anti-VEGF therapy is initiated in the setting of a suspected non-vascularized lesion, and the fluid appears unresponsive to therapy, then it is perfectly reasonable to inject the patient and perform OCT imaging one-to-two weeks later, when the treatment response should be maximal, to look for a response.  

If no response is seen, then the fluid probably is not dependent on vascular endothelial growth factor. If a response does occur, then the lesion is probably in an environment with an overabundance of VEGF, and monthly therapy is just inadequate to suppress the exudation.

Another strategy to use when the lesion appears unresponsive to anti-VEGF therapy, but the clinician is uncomfortable withdrawing therapy, is to slowly extend the interval and follow the lesion with OCT to determine if more fluid accumulates. The cases here demonstrate these management dilemmas.

Drusen, No Sign Of MNV
A 69-year-old woman was referred for a second opinion. She was originally diagnosed with neovascular AMD in the left eye and had received multiple anti-VEGF intravitreal injections, the last about six weeks
before her visit. Visual acuity was 20/25 in the left eye, and a fundus exam revealed confluent soft drusen (Figure 1).

SD-OCT imaging of the left eye showed two large drusen with subretinal fluid in between their peaks. However, FA did not show any leakage or sign of MNV. We made the decision to observe with serial SD-OCT imaging, and the subretinal fluid remained stable.

Non-vascularized Serous PED
A 72-year-old man presented with blurred vision in his right eye. VA was 20/100 in the eye. A fundus exam revealed confluent drusen, pigment and a PED (Figure 2). SD-OCT imaging revealed a predominantly serous PED with overlying subretinal fluid.

He received monthly injections of aflibercept (Eylea, Regeneron) for the next seven months, during which the SD-OCT findings and VA remained unchanged. FA and ICGA did not show any sign of MNV. We stopped treatment and the lesion remained unchanged.

This lesion is characteristic of a non-vascularized, predominantly serous PED in AMD. Over time, these lesions will collapse into GA.

Overlying Subretinal Fluid
An 81-year-old woman, who was being followed for dry AMD in both eyes, presented with decreased vision in the left eye. VA was 20/30 in that eye. A fundus exam revealed a central PED with adjacent drusen (Figure 3, page 45). SD-OCT showed a predominantly serous PED with overlying subretinal fluid.

 
 Figure 3. Color fundus
photography of the left eye (A) demonstrates central pigment epithelial detachment with adjacent drusen. Spectral-domain optical coherence tomography images at the fovea (B1–B5) at baseline, and months five (after five aflibercept injections), 13 (after three more injections), 20 (after two more injections) and 26 (after three more injections), respectively, show  the size of the PED and overlying subretinal fluid remain relatively unchanged. SD-OCT angiography does not show any sign of neovascularization (C1-C3).
She received 13 aflibercept injections in that eye over the next 26 months with intervals ranging from four to 14 weeks. The size of the PED and its overlying subretinal fluid remained unchanged at each visit. SD-OCT angiography did not reveal any evidence of neovascularization. Her visual acuity remained at 20/30 during the course of treatment.

‘Dry’ AMD a Misnomer?
These cases are all examples of subretinal fluid and drusen or PEDs in non-vascularized (“dry”) AMD unresponsive to anti-VEGF therapy. The question that arises in all of them is what is the source of the fluid in these lesions. The subretinal fluid is most likely the result of dysfunction of the RPE and its inability to pump fluid from the retina; the serous PEDs likely result from the fluid being pumped from the RPE and trapped within a lipid-laden, hydrophobic Bruch’s membrane. However, the exact mechanisms remain unproven.

 
Regardless, these lesions occur frequently and need to be recognized as masquerading as neovascular AMD. Moreover, these lesions demonstrate that the term “dry” AMD is a misnomer and should be avoided. Perhaps more appropriate terminology would be non-neovascular and neovascular AMD.

When subretinal fluid overlies the top of a PED, rather than on the edge of the PED, without associated intraretinal fluid, blood or a notch, then most likely the PED is not vascularized and will not respond to anti-VEGF therapy. Proceed with caution.  RS

REFERENCES
1. Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet. 2012;379:1728–1738.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444.
3. Tan AC, Simhaee D, Balaratnasingam C, Dansingani KK, Yannuzzi LA. A perspective on the nature and frequency of pigment epithelial detachments. Am J Ophthalmol. 2016 Sep 13 [Epub ahead of print]
4. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration:
year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58.
5. Sikorski BL, Bukowska B, Kaluzny JJ, Szkulmowski M, Kowalczyk A, Wojtkowski M. Drusen with accompanying fluid underneath the sensory retina. Ophthalmology. 2011;118:82-92.
6. Madjarov B, Rosenfeld PJ. Serous PEDs with associated subretinal fluid unresponsive to anti-VEGF therapy. Invest Ophthalmol Vis Sci. 2009;50:238.